GENERAL ORDER

GENERAL ORDER 320.13

WMD Nerve Agent Antidote Kits

EMERGENCY SERVICES BUREAU

Issue Date: January 10, 2007
Revision Date: September 21, 2020

1 APPLICABILITY

2 All Operational Personnel

3 POLICY

7

8

9

10

11

12 13

14

15

16

17

18

19 20

21

22

23 24

25

26

27

28

- 4 In an effort to protect operational personnel in the event of a terrorist attack utilizing nerve
- 5 agents, the Howard County Department of Fire and Rescue Services (Department) strategically
- 6 deploys Weapons of Mass Destruction (WMD) Nerve Agent Antidote Kits.

DEFINITIONS

- Nerve Agents A group of highly toxic chemicals that are potent, long acting, and bind to acetylcholine irreversibly unless antidote(s) are given.
- ➤ MARK I An antidote given for nerve agent poisoning consisting of two (2) autoinjectors containing Atropine and two (2) Pam-Chloride.
- ➤ **CANA** A medication administered in severe poisonings to relax muscle tissue and eliminate seizures.

PROCEDURES

GENERAL:

- WMD Nerve Agent Antidote Kits will be strategically distributed by EMS Operations to field apparatus and command vehicles based on medication availability. Kits will include MARK1 and CANA antidotes, when available from manufacturers, for Department operational personnel assigned to the given apparatus or vehicle. Additional and/or higher numbers of antidote kits may be placed on specific apparatus or command vehicles based on medication availability.
- All operational personnel shall review the "Maryland Medical Protocols for Emergency Medical Services Clinicians" with respect to protocols governing administration of MARK 1 and CANA Kits. Note: MMP requires the auto-injector of CANA be administered only by an ALS provider when three MARK I/DuoDote kits are administered in a severe exposure.



GENERAL ORDER

 Attachment A outlines potential signs and symptoms and treatment for nerve agent incidents. A guide is also included in each WMD Antidote Kit.

30 31 32

33

34

35

36 37

38

39

40

29

WMD ANTIDOTE KIT STORAGE AND SECURITY:

- The WMD Nerve Agent Antidote Kits shall be placed in an interior storage area or compartment. This is required to minimize degradation of the medications and to provide the additional security requirement of the medications.
- The WMD Nerve Agent Antidote Kits will be secured by the supplied combination padlock and a numbered inventory control tag. All padlocks will have the same combination and personnel can contact a Medical Duty Officer if forgotten.
- The exterior of the WMD Nerve Agent Antidote Kits will be labeled as follows: WMD KIT, Unit assigned, and MARK1 and CANA expiration dates. Example: WMD KIT, SQD-1, MARK1 EXP. MM/YY, CANA EXP. MM/YY.

41 42 43

44

45

46 47

48

49

50

51

52

WMD ANTIDOTE KIT TRACKING LOG:

- All WMD Nerve Agent Antidote Kits carried on apparatus will be checked as outlined:
 - During the daily DOT inspection of the apparatus, the WMD Antidote Kit will be inspected to ensure that the WMD Antidote Kit (Pelican case) is labeled, secured with the padlock, and that the numbered inventory control tag is correct and in place.
 - The number on the inventory control tag should be recorded daily on the WMD Nerve Agent Antidote Kit Tracking Log (Attachment B). If for any reason the numbered control tag is broken or missing, the WMD Nerve Agent Antidote Kit must be inventoried, retagged, and noted on the Tracking Log. Medical Duty Officers carry additional tags if needed.

53 54 55

56

57

58

• The Tracking Logs shall be collected by the Station Captain at the end of each month for apparatus and command vehicles assigned to their station. All Tracking Logs will be maintained at the station level for review by Emergency Services on demand for a period of three years.

59 60 • Any incomplete QA logs, or logs with unreported discrepancies, will be investigated with appropriate disciplinary actions, as needed.

61

REFERENCES

None

62

SUMMARY OF DOCUMENT CHANGES

- 64
- Updated to current GO format
 Language revised to reflect WMD kits will be strategically deployed instead of every

apparatus and vehicle

65 66

63

67



GENERAL ORDER

FORMS	/ATTA	CHMENTS
I O ILIVIO		

- Attachment A: Signs, Symptoms, and Treatment of Nerve Agents
 - Attachment B: WMD Nerve Agent Antidote Tracking Log

APPROVED

69

71

72

90

73		
74		
75		0.
76		16/11/6-
77		on must
78		William Anuszewski, Fire Chief
79		Office of the Fire Chief
80		
81		
82		
83	Author:	
84		
85		
86		
87		550C
88		
80		Span Alliger Agristant Chief

Emergency Services Bureau



GENERAL ORDER

91		Attachment A
92		Signs, Symptoms and Treatment of Nerve Agents
93		
94	•	PRESENTATION: "SLUDGE"
95		S- Salivation
96		L- Lacrimation (tearing)
97		U- Urination
98		D- Defecation
99		G- Gastrointestinal; pain/gas
100 101		E- Emesis (vomiting)
102	•	Also possible are pinpoint pupils, muscle twitching, and convulsions.
103	•	NOTE: If WMD is suspected, IMMEDIATELY don appropriate level of PPE (Structural FF
104		gear with SCBA is considered to be a minimal level for WMD).
105 106	SEVE	RITY OF EXPOSURE:
107	•	Vapor Poisoning- Effects start within seconds to a minute or two.
108		Mild to Moderate: Small or Pinpoint Pupils, Redness and/or, Eye pain, Dim or
109		blurred vision, Trouble Breathing, Vomiting, Diarrhea, Discharge from nasal
110		mucous membrane (Runny nose).
111		 Severe: Loss of Consciousness, seizures, apnea, and flaccid paralysis. Provider
112		will not be able to self-treat, due to severity.
113		, , , , , , , , , , , , , , , , , , ,
114	•	Liquid Poisoning- Effects start in minutes to hours.
115		 Mild to Moderate: Sweating and Fasciculation's at site of Exposure, Nausea,
116		Vomiting, Diarrhea, Weakness.
117		 Severe: Same as for Vapor, but after a 1 to 30 minute asymptomatic interval
118		
119	TREAT	TMENT:
120	•	Remove patient from contaminated area and remove contaminated clothing. <u>DO NOT</u>
121		TREAT If the only symptoms are miosis (unless eye pain is severe), or rhinorrhea (runny
122		nose unless severe).
123	•	MILD TO MODERATE POISONING:
124		 Administer one MARK 1 antidote kit (2 auto-injectors).
125		 Repeat with second MARK1 Kit in 10 minutes, if symptoms remain.
126		o Failure to respond (no dry mouth, no decrease in secretions) confirms the need
127		to administer the additional dose(s).
128		 Provide Oxygen and supportive care.
129		
130	•	SEVERE POISONING:
131		 Administer three MARK I antidote kits (6 auto-injectors). Provider will not be
132		able to self-treat (buddy care needed), due to severity.
133		 Provide intubation and ventilation with Oxygen (Initial ventilation will be difficult

because of airway resistance; atropine will relieve this).

134



GENERAL ORDER

135	
136	
137	

- Administer CANA (Diazepam), 10mg auto-injector if the patient is convulsing (ALS only, no consult required) after 3 MARK I kits have been administered.
- Additional doses of 2mg of Atropine may be repeated every 5 minutes until secretions diminish or airway resistance is less or normal.

138139140

MONITORING:

141 142 • Provide supportive care including pulse oximeter and cardiac monitoring, IV therapy, and consult as soon as possible.



GENERAL ORDER

143 Attachment B 144

	WMD Kit Tracking Log						
	Attachment B: General Order 320.13						
Instruction	ons: Loa	shall be completed during each daily/weekly check	as per General Order.				
		tained as specified in order.					
_							
UNIT:		MONTH:	YEAR:				
DATE	TIME	INVENTORY CONTROL #	SIGNATURE	EID#	COMMENTS		
1							
2							
3				1			
4				1			
5							
6							
7							
8							
9							
10							
11 12							
13							
14							
15							
16							
17							
18							
19							
20							
21							
22							
23							
24							
25							
26							
27				1			
28				1			
29				1			
30							

145